Celldex’s anti-KIT antibody meets endpoints in two Phase III CSU trials

Phase 3positiveanti-KIT antibodyPositive

AI Analysis

Summary

Celldex's anti-KIT antibody met endpoints in two Phase III trials for chronic spontaneous urticaria (CSU). The company previously terminated the antibody's separate development program in peripheral neuropathy (PN).

Clinical Trial Data

Phase

Phase III

Primary Endpoint

Met

Outcome Details

Met endpoints in two Phase III CSU trials

Importance:8/10

Sentiment:

0.85

Phase 3Positive DataAnti-KIT AntibodyCSUProgram Termination

Related Companies

$CLDX

Read the original article

Published by Clinical Trials Arena on September 22, 2026 2:36 PM

Read Original